Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BIOENGINEER.ORG
bioengineer.org > short-rna-reads-underestimate-a-to-i-rna-editing-long-read-sequencing-reveals

Short RNA Reads Underestimate A-to-I RNA Editing, Long-Read Sequencing

10+ hour, 47+ min ago   (89+ words) A widespread blind spot in one of genomics’ most routine measurements has been brought into sharp focus by a new study comparing short-read and long-read transcriptome sequencing. Researchers report that next-generation sequencing, the short-read workhorse of modern RNA analysis, systematically…...

BIOENGINEER.ORG
bioengineer.org > prime-editing-gets-a-size-upgrade-researchers-insert-large-dna-fragments-with-precision

Prime Editing Gets a Size Upgrade: Researchers Insert Large DNA Fragments

14+ hour, 55+ min ago   (653+ words) The gene-editing field has long faced a stubborn trade-off. Tools such as CRISPR-Cas9 excel at cutting DNA and at making small, targeted changes, but installing large pieces of genetic material into a genome at a precise location — without causing collateral…...

BIOENGINEER.ORG
bioengineer.org > crispr-methylation-editing-rewrites-the-cancer-epigenome-toward-causation

CRISPR Methylation Editing Rewrites the Cancer Epigenome Toward Causation

1+ day, 2+ hour ago   (67+ words) Cancer has long been understood as a disease of the genome, driven by mutations that rewire the instructions encoded in DNA. Over the past three decades, however, a parallel truth has crystallized: cancer is equally a disease of the epigenome,…...

UnionLeader.com
unionleader.com > news > scitech > scientist-jay-hoying-explores-frontiers-of-tissue-therapeutics > article_599332be-aa00-42b4-b71d-5f9b281bdfd3.html

Scientist Jay Hoying explores frontiers of tissue therapeutics

1+ day, 11+ hour ago   (639+ words) The BioAssemblyBot, or BAB for short, is a robotic platform with a multi-access arm. An instrument tells BAB what to do to build specific tissue. Jay Hoying can’t remember a time he didn’t want to be a scientist. He started…...

Chronicle Live
chroniclelive.co.uk > news > north-east-news > newcastle-researcher-share-66m-pioneering-34600075

Newcastle researcher to share £66m for pioneering gene-editing project

2+ day, 15+ hour ago   (527+ words) A Newcastle academic is to share part of a £66m funding grant as part of cutting edge research into "programming" a key aspect of our DNA. Jim Stewart, a senior lecturer at Newcastle University, has been awarded the funding through the…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > translational-research > riaans-therapeutic-odyssey-chapter-2-the-researchers

Riaan’s Therapeutic Odyssey – Chapter 2: The Researchers

2+ day, 14+ hour ago   (641+ words) By Jonathan D. Grinstein, PhD Could an academic laboratory build genetic medicines for diseases the traditional drug-development model leaves behind? Sena-Esteves sees that mismatch repeatedly. “I wish it wasn’t that way—that we had plenty of money and could just work…...

BIOENGINEER.ORG
bioengineer.org > how-epigenetics-is-rewriting-the-philosophy-of-harm-and-benefit

How Epigenetics Is Rewriting the Philosophy of Harm and Benefit

2+ day, 9+ hour ago   (757+ words) A concept as old as moral philosophy itself is being shaken by one of modern biology’s most transformative fields. In a new analysis published in Epigenetics Communications, philosopher Agnes E....

goSkagit
goskagit.com > bioviva-secures-u-s-patent-for-htert-and-follistatin-344-gene-therapy-approach-to-age > article_f47bcfe0-6ea9-5069-a202-e7b076e4f2cf.html

BioViva Secures U.S. Patent for hTERT and Follistatin-344 Gene Therapy Approach to Age-Related Disorders

2+ day, 22+ hour ago   (25+ words) goSkagit - Manage Subscription (Pay Your Bill, Vacation Request, Update Account Info)...

TradingView
tradingview.com > news > urn:summary_document_transcript:quartr.com:4151752:0-mgx-lead-gene-editing-program-for-hemophilia-a-advances-to-clinic-with-strong-preclinical-results-and-funding

MGX: Lead gene editing program for Hemophilia A advances to clinic with strong preclinical results and funding

2+ day, 17+ hour ago   (81+ words) tradingview.com MGX: Lead gene editing program for Hemophilia A advances to clinic with strong preclinical results and funding The session highlighted a proprietary gene editing platform with a lead program, MGX-001, advancing toward clinical trials for Hemophilia A, showing…...